Group 1 - The core viewpoint of the news is that Chengyi Pharmaceutical successfully participated in the national organized procurement and has four products selected for the procurement period ending December 31, 2028 [1] - The four selected products include Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection, with Glucosamine Capsules being a key product that accounts for approximately 40% of the first-year demand reported by institutions [1] - The revenue from Glucosamine Capsules reached 345 million yuan in the first three quarters of 2025, surpassing the total revenue of 335 million yuan for the entire year of 2024, with its revenue share increasing from 46.88% to 57.85% [1] Group 2 - The stock price of Chengyi Pharmaceutical has shown a fluctuating trend over the past seven trading days, closing at 11.77 yuan on February 12, 2026, with a single-day decline of 1.18% and a total trading volume of 54.63 million yuan [2] - The stock reached a high of 11.96 yuan and a low of 11.58 yuan during this period, with a cumulative fluctuation of 1.64% over five days [2] - The technical indicators suggest a pressure level at 12.37 yuan and a support level at 11.18 yuan, with recent MACD indicators showing weakness, while KDJ indicators indicate short-term overbought conditions [2]

Core Viewpoint - Chengyi Pharmaceutical (603811) announced that four of its products have been selected for the national centralized procurement program, with a procurement period extending to December 31, 2028, covering nationwide regions [1] Group 1: Product Details - The four selected products include Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection, each targeting specific medical conditions such as osteoarthritis, heart failure, local anesthesia, and complications from chronic kidney disease [1] - Glucosamine Hydrochloride Capsules are indicated for the treatment and prevention of osteoarthritis, with selected specifications of 750mg in 120 capsules and 750mg in 60 capsules [1] - Torasemide Injection is aimed at patients with edema due to congestive heart failure and liver cirrhosis, with selected specifications of 2ml:10mg in 10 vials and 4ml:20mg in 5 vials [1] - Lidocaine Hydrochloride Injection serves as a local anesthetic and antiarrhythmic agent, with a selected specification of 5ml:0.1g in 5 vials [1] - L-Carnitine Injection is for patients with chronic kidney disease undergoing long-term dialysis, with selected specifications of 5ml:1g in 5 vials and 5ml:2g in 5 vials [1] Group 2: Revenue Contribution - Among the four products, Glucosamine Hydrochloride Capsules are the core product, contributing significantly to revenue, with projected sales of 334.89 million yuan in 2024, accounting for 46.88% of the company's total revenue for that year [2] - For the first three quarters of 2025, the revenue from Glucosamine Hydrochloride Capsules is expected to reach 345.37 million yuan, representing 57.85% of the company's revenue during that period [2] - The other three products have relatively smaller revenue contributions, with Torasemide Injection generating 6.55 million yuan in 2024 and 4.20 million yuan in the first three quarters of 2025, accounting for 0.92% and 0.70% of total revenue, respectively [2] - Lidocaine Hydrochloride Injection and L-Carnitine Injection have minimal revenue, with figures below 0.1% for the respective periods [2] Group 3: Procurement Process - The centralized procurement process involves a coalition of provinces and regions across the country, led by Jiangsu, Henan, and Guangdong provinces to conduct unified procurement [3] - During the procurement period, medical institutions will prioritize the use of the selected drugs and ensure the completion of the agreed procurement volume [3] - Any remaining procurement volume after calculating the volume-based ratio can be selected from other companies that meet the bidding criteria [3]

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. announced participation in the national organized procurement for the first to eighth batches, with four products proposed for selection, covering a procurement period until December 31, 2028 [1] Group 1: Procurement Details - The four products proposed for selection are Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection [1] - The procurement is organized by a coalition of provinces and the Xinjiang Production and Construction Corps, with Jiangsu, Henan, and Guangdong provinces leading the unified national procurement [1] - Selected drugs will be prioritized for use by medical institutions, ensuring the completion of the agreed procurement volume [1] Group 2: Financial Impact - Glucosamine Hydrochloride Capsules are the company's main product, projected to generate revenue of 335 million yuan in 2024, accounting for 46.88% of total revenue [1] - For the first three quarters of 2025, revenue from Glucosamine Hydrochloride Capsules is expected to reach 345 million yuan, representing 57.85% of total revenue [1] - The other three products have relatively smaller revenue contributions [1] Group 3: Uncertainties and Risks - The final results of the proposed selections remain uncertain, and relevant procurement contracts have yet to be signed [1] - The quantity of selected products is not clearly defined, and production and sales are subject to policy and market environment influences [1]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 2 月 9 日，浙江诚意药业股份有限公司（以下简称"公司"）参与 了国家组织集采第 1-8 批协议期满品种接续采购的申报，根据国家组织集采药 品协议期满品种接续采购办公室（以下简称"接续采购办公室"）于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中选结果表 （LC-YPJX-2026-1）显示，公司产品盐酸氨基葡萄糖胶囊、托拉塞米注射液、 盐酸利多卡因注射液和左卡尼汀注射液拟中选本次接续采购，现将相关情况公 告如下： | 序 | 药品 | 规格包 | 适应症 | 拟中选价格 | 拟中选 区域报 | | 采购周 | 拟中选 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 名称 | 装 | 用于治疗和预防 | | 量 | | 期 | 区域 | | | | 750mg* 120 粒/ | 全身所有部位的 骨关节炎，包括膝 关节、肩关节、髋 | | | | | ...

Group 1 - The company, Chengyi Pharmaceutical (603811), stated on an interactive platform that it will disclose the number of shareholders at the end of the reporting period in its regular reports [1]

Group 1 - The core point of the article is that Chengyi Pharmaceutical (603811.SH) has a business of directly exporting raw materials to the European Union, although the revenue from EU exports has been a small proportion of the company's overall revenue in recent years [2]

Core Viewpoint - The company has successfully completed the registration process for Eicosapentaenoic Acid Ethyl Ester capsules and is preparing for compliance checks to begin production [1] Group 1: Regulatory Compliance - The company’s raw material production facility has passed multiple GMP audits by Australia's TGA since 1998, with the most recent GMP certificate obtained in January 2025 [1] - The facility has also successfully undergone on-site audits and re-evaluations by the US FDA, indicating its capability to produce the capsules in a GMP-certified environment [1] Group 2: Production Readiness - The Eicosapentaenoic Acid Ethyl Ester soft capsule has received the Drug Registration Certificate, and the production workshop is preparing for compliance checks [1] - Production can commence immediately after passing the compliance checks [1]

Core Viewpoint - Chengyi Pharmaceutical (603811) indicated that its R&D investment for 2026 will be disclosed in relevant periodic reports [1] Group 1 - The company responded to investor inquiries on an interactive platform [1]

Group 1 - The core focus of the news is the establishment of the "Biopharmaceutical Innovation Alliance" in Qiantang District, aimed at addressing challenges in the biopharmaceutical industry such as long R&D cycles and complex intellectual property layouts [1][2] - Qiantang District has developed into a mature ecosystem for biopharmaceutical innovation, with over 1,800 companies in Hangzhou Medical Port, including 7 of the top 10 global pharmaceutical companies and 35 "quasi-unicorn" enterprises [2][3] - The alliance's theme is "AI + Biopharmaceuticals," aligning with national strategies in pharmaceutical technology, and aims to create a tighter collaboration network among industry, academia, and research [2][3] Group 2 - The biopharmaceutical industry in Qiantang has a revenue exceeding 50 billion yuan, supported by a 500 billion yuan industrial fund matrix to provide financial backing throughout the lifecycle of enterprises [3] - The region has established a preliminary industrial closed loop in the "AI + Biopharmaceutical" field, including AI target discovery, automated experiments, and digital clinical trials [2][3] - Qiantang District aims to achieve a biopharmaceutical industry scale exceeding 100 billion yuan by 2028, with a focus on collaboration among universities, platforms, enterprises, and the industry chain [3]